Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 degrader for extensive evaluation for the treatment of human cancers and other human diseases.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-03-23
DOI
https://doi.org/10.1021/acs.jmedchem.5c03767
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

D. H. Sun, S Wang, Meilin Wang, Ranjan Kumar Acharyya et al.
Journal of Medicinal Chemistry
Protein Degradation and Inhibitors
article

Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader

D. H. Sun, S Wang, Meilin Wang, Ranjan Kumar Acharyya, Rohan Kalyan Rej, Jelena Tošović, Hoda Metwally, Donna McEachern, Bo Wen, Haibin Zhou, Dimin Wu, Longchuan Bai, Mi Wang
article en

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 degrader for extensive evaluation for the treatment of human cancers and other human diseases.

Journal of Medicinal Chemistry
University of Michigan (US), Medicina (PL), Rogers (United States) (US)
Openalex Percentile: Top 12%
Protein Degradation and Inhibitors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.